KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Non Operating Income (2016 - 2025)

Abbott Laboratories' Non Operating Income history spans 17 years, with the latest figure at $134.0 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 12.99% year-over-year to $134.0 million; the TTM value through Dec 2025 reached $548.0 million, up 45.74%, while the annual FY2025 figure was $548.0 million, 45.74% up from the prior year.
  • Non Operating Income for Q4 2025 was $134.0 million at Abbott Laboratories, down from $150.0 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $176.0 million in Q2 2023 and bottomed at -$10.0 million in Q2 2024.
  • The 5-year median for Non Operating Income is $101.0 million (2022), against an average of $100.0 million.
  • The largest annual shift saw Non Operating Income soared 6000.0% in 2021 before it crashed 105.68% in 2024.
  • A 5-year view of Non Operating Income shows it stood at $63.0 million in 2021, then increased by 7.94% to $68.0 million in 2022, then soared by 60.29% to $109.0 million in 2023, then soared by 41.28% to $154.0 million in 2024, then decreased by 12.99% to $134.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABT's Non Operating Income are $134.0 million (Q4 2025), $150.0 million (Q3 2025), and $137.0 million (Q2 2025).